Clinical trials: Acute Myocardial Infarction (AMI)
Nonfatal Myocardial Infarction, Coronary Death
Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Heart Disease Death
The purpose of this study is to estimate the risk of myocardial infarction (MI)/coronary death associated with use of monotherapy low dose ASA (single antiplatelet) as well as concomitant use of monotherapy low dose ASA and…
- Trial name
- NCT01360073
- Where
- 2 sites in Spain, Sweden
- Volunteers
- 42,542 people
- Sponsor
- AstraZeneca
Nonfatal Myocardial Infarction, Coronary Death
Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Death
The purpose of this study is to estimate the risk of myocardial infarction (MI)/coronary death associated with use of monotherapy low dose ASA (single antiplatelet) as well as concomitant use of monotherapy low dose ASA and…
- Trial name
- NCT01360047
- Where
- Spain
- Volunteers
- 39,513 people
- Sponsor
- AstraZeneca
Left Ventricular Dysfunction
Bone Marrow Derived Mononuclear Cells For Myocardial Regeneration
Evaluative pilot study for safety and feasibility with administration of autologous bone bone marrow derived mononuclear cells by endoventricular catheter into the normal border zone fo the ischemic lesion.
- Trial name
- NCT00938847
- Testing
- PCI
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Asklepios proresearch
Myocardial Infarction
STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
This study aims at evaluating, in a proof of concept approach, the outcome of patients presenting with acute ST-elevation myocardial infarction within 3 hours of symptom onset in either a pre-hospital setting or community…
- Trial name
- NCT00623623
- Testing
- primary PCI, enoxaparin, catheterisation
- Where
- 201 sites in Austria, Belgium and 14 more
- Volunteers
- 1,899 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Acute Myocardial Infarction
Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes
The primary objective was to demonstrate a difference between two insulin strategies, one targeting postprandial (PP) hyperglycemia and the other targeting fasting and interprandial hyperglycemia, on time until the first combined…
- Trial name
- IONM (NCT00191282)
- Testing
- Insulin lispro, Human insulin isophane suspension (NPH), Insulin glargine
- Where
- 17 sites in Canada, Croatia and 15 more
- Volunteers
- 1,116 people
- Sponsor
- Eli Lilly and Company
ST Elevation Myocardial Infarction
Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients
This phase IIa study is to identify the efficacy and safety of IC(intracoronary) and IV(Intravenous) administrations of UMSC01 in patients with STEMI .
- Trial name
- NCT06147986
- Testing
- Allogeneic umbilical cord mesenchymal stem cells, Control group
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- Ever Supreme Bio Technology Co., Ltd.
Myocardial Infarction (MI)
Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction
Thi is is a multi-center, randomized, single-blind, parallel group clinical trial to evaluate the efficacy and safety of the intravenious thrombolysis with Revelise® (GENERIUM, Russia) in comparosin with the Actilyse® (Boehringer…
- Trial name
- NCT07146360
- Testing
- Revelise (GENERIUM, Russia), Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)
- Where
- 22 sites in Russia
- Volunteers
- 180 people
- Sponsor
- AO GENERIUM
Acute Coronary Syndrome, Acute Myocardial Infarction
Sicilian Administrative Data Base Study in Acute Coronary Syndrome Patients
Thi is an observational, non interventional, cohort analysis by using administrative databases (drugs treatment, laboratory and diagnostic tests, specialist visits and hospitalizations) of Sicilia region to evaluate treatment…
- Trial name
- HEALTH-DB ACS (NCT01678339)
- Where
- Italy
- Sponsor
- AstraZeneca
Myocardial Infarction
Surveillance of Patients With Suspected Acute Myocardial Infarction That Receive Early Inhospital Thrombolysis With Metalyse
Obtaining data on efficacy (e.g. complete ST-segment resolution) depending on the time of treatment initiation and safety of prehospital and early hospital thrombolysis with Metalyse® in a real life setting outside clinical…
- Trial name
- NCT02194153
- Testing
- Metalyse weight-adjusted
- Volunteers
- 351 people
- Sponsor
- Boehringer Ingelheim
Acute Myocardial Infarction
An Observational Study of TNKase in Patients Enrolled in the National Registry of Myocardial Infarction 4 and 5 (POST)
The POST study comprised patients whose data were entered into the NRMI 4 and 5 databases. NRMI is a prospective, observational study of patients presenting with AMI in the United States.
- Trial name
- NCT00669045
- Volunteers
- 253,668 people
- Sponsor
- Genentech, Inc.
Acute Myocardial Infarction, Restenoses, Coronary
Abbott Vascular Medical Device Registry
The AV-MDR is a prospective, non-randomized, open-label, multi-center registry. The purpose of the AV-MDR study is to proactively collect and evaluate clinical data on the usage of the devices in scope within their intended use…
- Conditions
- Acute Myocardial Infarction, Restenoses, Coronary, Coronary Artery Lesions, Venous Embolism
- Trial name
- AV-MDR (NCT04573660)
- Testing
- Coronary and peripheral stents, Pacing catheters, Vascular plugs
- Where
- 37 sites in United States, Australia and 12 more
- Volunteers
- 3,784 people
- Sponsor
- Abbott Medical Devices
Acute Coronary Syndrome
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
This is a randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate initial safety and efficacy of GW856553 in subjects with NSTEMI.
- Trial name
- Solstice (NCT00910962)
- Testing
- GW856553
- Where
- 108 sites in United States, Australia and 7 more
- Volunteers
- 526 people
- Sponsor
- GlaxoSmithKline
Myocardial Ischemia
Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes
MERLIN-TIMI 36 is a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of ranolazine during acute and long-term treatment in approximately…
- Trial name
- NCT00099788
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 6,560 people
- Sponsor
- Gilead Sciences
Acute Myocardial Infarction
Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
This was a double-blind, randomized, placebo-controlled study that was designed to enroll a total of 225 participants with de novo anterior wall acute ST-segment elevation myocardial infarction (STEMI) due to a lesion of the left…
- Trial name
- AMICI (NCT01781390)
- Testing
- Mesenchymal Precursor Cells (MPC) 12.5 M, Mesenchymal Precursor Cells (MPC) 25 M
- Volunteers
- 106 people
- Sponsor
- Mesoblast, Inc.
STEMI
STENTYS Self-expanding Versus Balloon-expandable Stent in Acute Myocardial Infarction (AMI)
Study hypothesis: the Stentys self-expandable Stent results into a better alignment of the struts to the vessel wall than a balloon-expandable stent within a few days after the procedure in acute myocardial infarction patients.
- Trial name
- APPOSITION ll (NCT01008085)
- Testing
- Stentys coronary stent, Balloon-expandable stent
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Stentys
Myocardial Infarction
MiSaver® Stem Cell Treatment for Heart Attack (Acute Myocardial Infarction)
The objective of the present study is to establish the safety and efficacy of MiSaver® Stem Cell Treatment After a Heart Attack (Acute Myocardial Infarction)
- Trial name
- MiSaver® (NCT04050163)
- Testing
- MiSaver®
- Where
- 2 sites in Taiwan
- Volunteers
- 11 people
- Sponsor
- Honya Medical Inc
Diabetes Mellitus, Type 2, Acute Coronary Syndrome
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.
- Trial name
- EXAMINE (NCT00968708)
- Testing
- Alogliptin
- Where
- 908 sites in United States, Argentina and 48 more
- Volunteers
- 5,380 people
- Sponsor
- Takeda
Stroke, Stroke, Acute Ischemic
NeuroAiD Patient-Reported Outcomes in Patients With Mild to Moderate Ischemic Stroke
This is a randomized, controlled, open-label study of MLC901 (NeuroAiD™ II) in patients with mild to moderate ischemic stroke. Eligible participants will be randomized in a 1:1 ratio to receive MLC901 in combination with standard…
- Conditions
- Stroke, Stroke, Acute Ischemic, Stroke, Ischemic, Stroke, Cryptogenic
- Trial name
- NAiD-PRO (NCT07828210)
- Testing
- MLC901, Standard treatment for acute ischemic stroke
- Where
- Vietnam
- Volunteers
- 80 people
- Sponsor
- EVD Pharmacy and Medical Company Limited
Acute Myocardial Infarction, Moderate Renal Impairment
A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction
This study is a phase 2, multicenter, double-blind, randomized, placebo controlled, parallel-group study to investigate the renal safety and tolerability of multiple dose intravenous (IV) administration of CSL112 compared with…
- Trial name
- NCT02742103
- Testing
- CSL_112
- Where
- 31 sites in United States, Germany and 3 more
- Volunteers
- 83 people
- Sponsor
- CSL Behring
Acute Myocardial Infarction
Safety and Efficacy Evaluation of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With AMI
Development of myocardial reparative therapy for the treatment of acute ischemic cardiac disease, based on the intracoronary administration of allogeneic Cardiac Stem Cells (CSCs) to ameliorate myocardial cell death and promote…
- Trial name
- CAREMI (NCT02439398)
- Testing
- Allogeneic human cardiac stem cells (CSCs), Human Serum Albumin-HSA 5%
- Where
- Spain
- Volunteers
- 55 people
- Sponsor
- Coretherapix